Nurse/AH welcome all to join us @myeloma-society.bsky.social travel safe - c u in Rio!
events.jspargo.com/ims24/CUSTOM...
events.jspargo.com/ims24/CUSTOM...
September 15, 2024 at 12:37 AM
Nurse/AH welcome all to join us @myeloma-society.bsky.social travel safe - c u in Rio!
events.jspargo.com/ims24/CUSTOM...
events.jspargo.com/ims24/CUSTOM...
Really excellent multidisciplinary panel in #IMS24 nursing & AHP session @myeloma-society.bsky.social annual meeting on real-world solutions to treatment delivery in #myeloma
@rahulbanerjeemd.bsky.social @bethfaiman.bsky.social
@rahulbanerjeemd.bsky.social @bethfaiman.bsky.social
September 25, 2024 at 3:56 PM
Really excellent multidisciplinary panel in #IMS24 nursing & AHP session @myeloma-society.bsky.social annual meeting on real-world solutions to treatment delivery in #myeloma
@rahulbanerjeemd.bsky.social @bethfaiman.bsky.social
@rahulbanerjeemd.bsky.social @bethfaiman.bsky.social
IMS President Philippe Moreau reviewed IMS’ mission, membership, and educational initiatives—including Genomics and Immune-Effector Therapies workshops and IMSound, a new audio series. #IMS24
September 25, 2024 at 4:07 PM
IMS President Philippe Moreau reviewed IMS’ mission, membership, and educational initiatives—including Genomics and Immune-Effector Therapies workshops and IMSound, a new audio series. #IMS24
Saad Usmani, MD, shared exciting FIRST results from CEPHEUS study of a Dara quad in transplant-ineligible/transplant-deferred NDMM.
Quads continue to improve outcomes & take spotlight in frontline induction. @szusmani.bsky.social #IMS24
Quads continue to improve outcomes & take spotlight in frontline induction. @szusmani.bsky.social #IMS24
September 28, 2024 at 10:33 AM
Saad Usmani, MD, shared exciting FIRST results from CEPHEUS study of a Dara quad in transplant-ineligible/transplant-deferred NDMM.
Quads continue to improve outcomes & take spotlight in frontline induction. @szusmani.bsky.social #IMS24
Quads continue to improve outcomes & take spotlight in frontline induction. @szusmani.bsky.social #IMS24
T-14 days until #IMS24! @rahulbanerjeemd.bsky.social
Are you ready for #IMS24?🤩 In just a few weeks, professionals from around the globe will gather to explore the latest in #myeloma research. Don’t be left behind! Whether in Rio de Janeiro or virtually, be part of the experience. Register today! ➡️ rb.gy/1h136x
September 10, 2024 at 11:00 PM
T-14 days until #IMS24! @rahulbanerjeemd.bsky.social
Today is the first day of #IMS24. Join us for the President's Address followed by the Keynote. View the program to see the exciting content for the day. rb.gy/b1iu3o
September 25, 2024 at 10:13 AM
Today is the first day of #IMS24. Join us for the President's Address followed by the Keynote. View the program to see the exciting content for the day. rb.gy/b1iu3o
Keynote speaker Anant Madabhushi, PhD, shared work on AI-enabled Pathomics—leveraging AI to identify and validate “digital biomarkers”, from radiology/pathology images to omics, for prognostication & treatment response prediction. #IMS24
September 25, 2024 at 4:08 PM
Keynote speaker Anant Madabhushi, PhD, shared work on AI-enabled Pathomics—leveraging AI to identify and validate “digital biomarkers”, from radiology/pathology images to omics, for prognostication & treatment response prediction. #IMS24
Don't forget, you can still access #IMS24 meeting content. If you registered for either in-person or virtual, login to the virtual platform to review all recorded sessions. virtual.imsannual.org/login
September 29, 2024 at 10:42 AM
Don't forget, you can still access #IMS24 meeting content. If you registered for either in-person or virtual, login to the virtual platform to review all recorded sessions. virtual.imsannual.org/login
1/ And since we can’t tweet during #IMS24, also worth highlighting CEPHEUS as another LBA!
D-VRd vs VRd in ASCT-ineligible #MMsm - large PFS benefit with CD38 addition even if no ASCT. Love simplicity of the last line: ASCT decision-making should not dictate induction choice!
D-VRd vs VRd in ASCT-ineligible #MMsm - large PFS benefit with CD38 addition even if no ASCT. Love simplicity of the last line: ASCT decision-making should not dictate induction choice!
September 8, 2024 at 1:30 PM
This session should be considered required viewing for anyone who takes care of myeloma patients -- Audience Member reacts to High Risk Disease session #IMS24
September 26, 2024 at 4:26 PM
This session should be considered required viewing for anyone who takes care of myeloma patients -- Audience Member reacts to High Risk Disease session #IMS24
Thank you to everyone who joined #IMS24, both in person and virtually. Save the date for next year's conference, taking place September 17-20 in Toronto, Canada. We look forward to seeing you in 2025!
September 29, 2024 at 10:38 AM
Thank you to everyone who joined #IMS24, both in person and virtually. Save the date for next year's conference, taking place September 17-20 in Toronto, Canada. We look forward to seeing you in 2025!
Are you ready for #IMS24?🤩 In just a few weeks, professionals from around the globe will gather to explore the latest in #myeloma research. Don’t be left behind! Whether in Rio de Janeiro or virtually, be part of the experience. Register today! ➡️ rb.gy/1h136x
September 6, 2024 at 3:18 PM
Are you ready for #IMS24?🤩 In just a few weeks, professionals from around the globe will gather to explore the latest in #myeloma research. Don’t be left behind! Whether in Rio de Janeiro or virtually, be part of the experience. Register today! ➡️ rb.gy/1h136x
It's Day 2 of #IMS24! Begin your morning at the Meet the Expert sessions at 7:00 AM. Get ready for a day packed with exciting events—be sure to check the program! rb.gy/b1iu3o
September 26, 2024 at 9:55 AM
It's Day 2 of #IMS24! Begin your morning at the Meet the Expert sessions at 7:00 AM. Get ready for a day packed with exciting events—be sure to check the program! rb.gy/b1iu3o
Don't miss this Meet the Expert session on Saturday, September 28 at #IMS24. Register now!➡️ rb.gy/1h136x
September 16, 2024 at 4:04 PM
Don't miss this Meet the Expert session on Saturday, September 28 at #IMS24. Register now!➡️ rb.gy/1h136x
Be sure to attend the session Moving the Paths to Approval: Regulatory Consideration during #IMS24. View the program here➡️ rb.gy/b1iu3o
September 16, 2024 at 3:02 PM
Be sure to attend the session Moving the Paths to Approval: Regulatory Consideration during #IMS24. View the program here➡️ rb.gy/b1iu3o
Visit Pavilion 3 for the Industry Symposium, supported by Bristol Myers Squibb, on the role of immune strategies in consolidation and maintenance. #IMS24
September 25, 2024 at 4:34 PM
Visit Pavilion 3 for the Industry Symposium, supported by Bristol Myers Squibb, on the role of immune strategies in consolidation and maintenance. #IMS24